Home / Services / Regulatory Affairs Services

Regulatory Affairs Services

Strategic regulatory roadmaps, CTD/eCTD publishing, product registration, dossier gap analysis, and global health authority compliance.

Regulatory StrategyCTD / eCTD PublishingEDA / FDA / EMA RegistrationGlobal Authority Liaison

Service Overview

In today's highly dynamic pharmaceutical landscape, securing timely market authorization and maintaining global regulatory compliance require deep domain expertise, rigorous technical oversight, and seamless communication with health authorities.

QEEMA Egypt provides end-to-end Regulatory Affairs Services designed for pharmaceutical, biopharmaceutical, medical device, and healthcare companies. From initial filing strategy to post-approval lifecycle management, our team of regulatory experts ensures your product dossier strictly meets the requirements of the Egyptian Drug Authority (EDA), US FDA, EMA, SFDA, MHRA, WHO, TGA, and Health Canada.

Core Scope & Technical Deliverables

Regulatory Strategy & Planning

Customized regulatory roadmaps, target market entry evaluation, submission pathways, and risk mitigation strategies tailored to regional guidelines.

  • Market entry strategy
  • Submission pathway evaluation
  • Risk mitigation roadmaps
CTD / eCTD Preparation & Publishing

Full compilation, formatting, hyperlinking, XML validation, and electronic submission publishing for Modules 1 through 5 in ICH/eCTD format.

  • ICH Modules 1-5 compilation
  • XML validation & hyperlinking
  • Electronic publishing readiness
Product Registration & Gap Analysis

Turnkey product registration management and comprehensive audit of existing regulatory files, Module 3 CMC data, and clinical summaries.

  • Pharma & biologic registration
  • Dossier gap analysis
  • Module 3 CMC verification
Authority Communication & Variations

Direct technical liaison with health agencies, rapid drafting of deficiency responses, and post-approval Type I/II variation management.

  • Deficiency letter responses
  • Type I/II variation management
  • Global authority communications

Implementation Methodology

1
Dossier Gap Audit & Requirement Mapping

Conducting an initial gap analysis of existing data against target authority guidelines (EDA/ICH) to pinpoint missing studies or formatting gaps.

2
Technical Content Compilation & Review

Our regulatory scientists author, structure, and verify Modules 1 through 5, ensuring technical accuracy in Module 3 CMC documentation.

3
eCTD Publishing & XML Validation

The dossier is electronically published using compliant eCTD software, complete with hyperlinking, bookmarking, and XML validation checks.

4
Submission & Authority Representation

Assisting in formal dossier submission to health authorities and managing ongoing communications, resolving any deficiency queries rapidly.

5
Post-Approval Variations & Renewals

Continuous lifecycle support ensuring variations (Type I/II) and annual renewals are maintained without market disruption.

Target Sectors & Applications

Our specialized consulting services cater to:

FDA (United States) & EMA (European Union) registration projects.
SFDA (Saudi Arabia), EDA (Egypt), and GCC regional health authority submissions.
Human finished pharmaceutical generic and brand product manufacturers.
Biopharmaceutical, biosimilar, and medical device producers.

Frequently Asked Questions

The Common Technical Document (CTD) specifies the standardized structure (Modules 1-5) for pharmaceutical dossier submission. The electronic CTD (eCTD) is the electronic format that includes XML backbones, strict hyperlinking, lifecycle management tags, and digital validation required by EDA, FDA, and EMA.

When health authorities like EDA or SFDA issue deficiency notes or requests for technical clarification, QEEMA's experts analyze the deficiencies, perform required data reviews, and draft authoritative response letters backed by technical data to secure rapid clearance.